Table 1.
Demographic and clinical characteristics of the five COVID-19 study cohorts.
| Study Samples | COVID-19 Patient Metadata | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| #Case vs. Control | Age median year (IQR) | Gender[%] | Co-morbidities [%] | Smoking[%] | BMI[IQR] | COVID-19 Severity [%] | Ethnicity[%] | Olink panels | Sampling matrix | Reference |
| ICU 43 vs. 25 |
58.7(17.7) | M=86 F=14 |
Heart diseases=12 Diabetes=16 Hypertension=40 Acute kidney injury=61 |
4.6 | 27.4(6.5) | Severe ARDS=100 | White=35 Black=7 Asia=9 Other=49 |
Infl., CVD II & III | Plasma | NA |
| GIM 48 vs. 50 |
66.1(25.2) | M=60 F=40 |
Heart diseases=15 Cancer=15 Diabetes=25 Hypertension=44 ESRD=13 Chronic kidney disease=4 Acute kidney injury=10 |
0.0 | 27.1(7.8) | Mild/Moderate=63 Severe=37 |
White=50 Black=13 Asia=4 Other=33 |
Infl., CVD II & III | Serum | No reference available |
|
*IMP 33 vs. 50 |
72.2(14.8) | M=71 F=29 |
Diabetes=62 ESKD=100 |
1.8 | NA | Mild/Moderate=51 Severe=49 |
White=29 Black=15 South Asia=33 Asia=7 Others=16 |
Infl., Immune Response CVD II & III | Plasma | (17) |
|
*REP 52 vs. 11 |
64.3(12.7) | M=70 F=30 |
Diabetes=63 ESKD=100 |
4.3 | NA | Mild/Moderate=29 Severe=71 |
White=24 Black=17 South Asia=26 Asia=15 Others=17 |
Infl., Immune Response CVD II & III | Serum | (17) |
|
*MGH 305 vs. 78 |
58.0(30.) | M=53 F=47 |
Heart diseases=16 Diabetes=36 Hypertension=48 Hyperlipidemia=22 Chronic lung disease=22 Kidney disease=13 Immunocompromised =8 |
3.6 | 29(8.0) | Mild/Moderate=69 Severe=31 |
Hispanic=54 Black=10 Not described=36 |
Olink® Explore 1536 | Plasma | (15) |
*These are the numbers used in the current analysis after removal of additional samples that have been measured from the same patients on successive time-points.
NA, Not available.